Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 3
Submit an article Journal homepage
1,172
Views
17
CrossRef citations to date
0
Altmetric
Editorial

Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease

Clive Ballard Wolfson Centre for Age-Related Diseases, King’s College London, Guy’s Campus, London, SE1 1UL, UK. [email protected]
,
Anne Corbett Alzheimer’s Society, Devon House, 58 St Katharine’s Way, London, E1W 1JX, UK
&
Samantha Sharp Alzheimer’s Society, Devon House, 58 St Katharine’s Way, London, E1W 1JX, UK
Pages 327-329 | Published online: 09 Jan 2014

References

  • Wimo A, Prince M. World Alzheimer Report. Alzheimer’s Disease International, London, UK (2010).
  • Ballard C, Sorensen S, Sharp S. Pharmacological therapy for people with Alzheimer’s disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. J. Alzheimers Dis.12, 53–59 (2007).
  • Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.1, CD001747 (2006).
  • Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev.15(2), CD001191 (2009).
  • Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev.25(1), CD001190 (2006).
  • Xie J, Brayne C, Matthews FE; Medical Research Council Cognitive Function and Ageing Study collaborators. Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ336, 258–262 (2008).
  • McGirr G, Compton SA. Drugs for dementia: the first year. An audit of prescribing practice. Ulster Med. J.69, 123–127 (2000).
  • Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ174, 1099–1105 (2006).
  • Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer’s disease taking galantamine for up to 48 months. Int. J. Geriatr. Psychiatry23, 207–214 (2008).
  • Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol.61, 252–256 (2004).
  • Courtney C, Farrell D, Gray R et al.; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363, 2105–2115 (2004).
  • Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology57, 613–620 (2001).
  • Winblad B, Grossberg G, Frölich L et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology69, 14–22 (2007).
  • Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet355, 314–315 (2000).
  • Wood RY, Giuliano KK, Bignell CU, Pritham WW. Assessing cognitive ability in research: use of MMSE with minority populations and elderly adults with low education levels. J. Gerontol. Nurs.32, 45–54 (2006).
  • Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J. Am. Geriatr. Soc.41, 346 (1993).
  • Moise P, Schwarzinger M, Um M-Y. Dementia Care in 9 OECD Countries: A Comparative Analysis. DELSA/ELSA/WD/HEA, Paris, France (2004).
  • National Audit Office. Improving Services and Support for People with Dementia. NAO, London, UK (2007).
  • Waldemar G, Phung KT, Burns A et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int. J. Geriatr. Psychiatry22, 47–54 (2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.